论文部分内容阅读
目的:分析经尿道膀胱肿瘤切除术(TURBT)联合吡柔比星灌注治疗浅表性膀胱癌患者后,患者肿瘤细胞活力和信号通路因子表达的影响。方法:将2010年1月至2015年1月间我院收治的113例浅表性膀胱癌患者分为观察组和对照组两组,观察组采用TURBT联合吡柔比星灌注治疗,对照组采用TURBT进行治疗;记录两组患者手术时间、置留导尿管时间,随访期间内膀胱穿孔、复发情况,随访时检测血清中VEGF-C、VEGF-B、VEGF-A、DKK-4、DKK-3、DKK-2、DKK-1、IL-2、PCNA、CA125蛋白水平和STAT5、STAT3、mTOR、JAK、AKT、PI3K mRNA水平。结果:观察组导尿管置留时间和临床复发率均显著低于对照组(P<0.05);观察组患者VEGF-C、VEGF-B、VEGF-A、DKK-4、DKK-3、DKK-2、DKK-1、IL-2、PCNA、CA125水平均显著低于对照组(P<0.05);观察组患者血清中STAT5、STAT3、mTOR、JAK、AKT、PI3K mRNA水平显著低于对照组;观察组患者不良反应发生率显著低于对照组,且差异存统计学意义(P<0.05)。结论:采用TURBT联合吡柔比星灌注治疗后,可有效降低浅表性膀胱癌患者的肿瘤细胞活力,下调mTOR信号通路因子表达,具有较好的临床疗效。
Objective: To analyze the effect of TURBT combined with pirarubicin on the activity of tumor cells and the expression of signal pathways in patients with superficial bladder cancer. Methods: One hundred and eleven patients with superficial bladder cancer who were admitted to our hospital from January 2010 to January 2015 were divided into observation group and control group. The observation group was treated with TURBT combined with pirarubicin and the control group TURBT. The time of operation, catheterization time, bladder perforation and recurrence during follow-up were recorded and the levels of VEGF-C, VEGF-B, VEGF-A, DKK- 3, DKK-2, DKK-1, IL-2, PCNA, CA125 and STAT5, STAT3, mTOR, JAK, AKT and PI3K mRNA levels. Results: The catheterization time and clinical recurrence rate in the observation group were significantly lower than those in the control group (P <0.05). The VEGF-C, VEGF-B, VEGF-A, DKK-4, DKK- (P <0.05). The levels of STAT5, STAT3, mTOR, JAK, AKT and PI3K in the observation group were significantly lower than those in the control group The incidence of adverse reactions in observation group was significantly lower than that in control group, and the difference was statistically significant (P <0.05). CONCLUSION: TURBT combined with pirarubicin can effectively reduce the tumor cell viability and down-regulate the expression of mTOR signaling pathway in patients with superficial bladder cancer, which has a good clinical efficacy.